Recent News
New Studies Demonstrate Clinical Utility and Validity of CancerTYPE ID Molecular Classifier
bioTheranostics Launches Precision Medicine Biomarkers
for Tumor Pathway Interrogation
CancerTYPE ID Linked with Improved Clinical Outcome & Longer Survival
New Study Reports: CancerTYPE ID Expands Tumor Type Coverage & Demonstrates Clinical Utility
CancerTYPE ID Now a Covered Benefit for Medicare Part B Patients
Data from Clinical Studies of CancerTYPE ID & Breast Cancer Index Presented at ASCO 2011
Recent Publications
Journal of Molecular Diagnostics: Performance & Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification (Erlander, et al)
Clinical Colorectal Cancer:
A Retrospective Study of Treatment Outcomes in Patients with CUP site & a Colorectal Cancer Molecular Profile
(Hainsworth,et al)
Community Oncology:
Molecular tumor classification using a 92-gene assay in the differential diagnosis of squamous cell lung cancer (McGee, et al)
The Oncologist:
Molecular Profiling of Unknown Primary Cancer (Greco, et al)
bioTheranostics develops and provides innovative oncology tests to support targeted disease management.
CancerTYPE ID® is a molecular test that uses the differential expression of 92 genes to aid in the determination of tumor site of origin.
Learn More >
Breast Cancer IndexSM is a prognostic biomarker that provides quantitative assessment of the likelihood of distant recurrence in patients diagnosed with estrogen receptor-positive, lymph node-negative breast cancer.
Learn More >
PRÉCISSM Precision Medicine by bioTheranostics
Includes biomarker profiles for non-small cell lung and colorectal cancer that detect clinically relevant tumor biomarkers.
Learn More >
Healthcare Professionals
Learn more about CancerTYPE ID®
Access Clinical Publications
Register for Clinical Updates
Request a Specimen Shipping Kit
Contact Medical Affairs
Patients and Caregivers
Learn about CancerTYPE ID
Learn More About Metastatic Cancers
+1 (877) 886-6739 client services
